Involvement of mast cells in systemic sclerosis

Sonosuke Yukawa, Kunihiro Yamaoka, Norifumi Sawamukai, Shohei Shimajiri, Kazuyoshi Saito, Yoshiya Tanaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Systemic sclerosis is characterized by tissue fibrosis, obliterative microangiopathy and immune abnormalities. The etiology of SSc is largely unknown and is known to be resistant to existing corticosteroid and immunosuppressive drugs. Therefore, establishment of a treatment strategy especially for SSc patients with organ involvement is strongly desired. Mast cells are widely recognized as effector cells in allergic disorders and other IgE-mediated immune responses. However, recently, mast cells have become known to play a role in bridging innate immunity and adaptive immunity. Additionally, there is growing evidence of mast cell to be involved in pathogenesis of rheumatoid arthritis, and is expected as a novel therapeutic target.We describe here the role of mast cell in SSc pathology and suggest as a novel therapeutic target.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalJapanese Journal of Clinical Immunology
Volume33
Issue number2
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Systemic Scleroderma
Mast Cells
Adaptive Immunity
Immunosuppressive Agents
Innate Immunity
Immunoglobulin E
Rheumatoid Arthritis
Adrenal Cortex Hormones
Fibrosis
Therapeutics
Pathology
Pharmaceutical Preparations

Keywords

  • Imatinib
  • Mast cell
  • Pulmonary arterial hypertension
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Yukawa, S., Yamaoka, K., Sawamukai, N., Shimajiri, S., Saito, K., & Tanaka, Y. (2010). Involvement of mast cells in systemic sclerosis. Japanese Journal of Clinical Immunology, 33(2), 81-86. https://doi.org/10.2177/jsci.33.81

Involvement of mast cells in systemic sclerosis. / Yukawa, Sonosuke; Yamaoka, Kunihiro; Sawamukai, Norifumi; Shimajiri, Shohei; Saito, Kazuyoshi; Tanaka, Yoshiya.

In: Japanese Journal of Clinical Immunology, Vol. 33, No. 2, 2010, p. 81-86.

Research output: Contribution to journalArticle

Yukawa, S, Yamaoka, K, Sawamukai, N, Shimajiri, S, Saito, K & Tanaka, Y 2010, 'Involvement of mast cells in systemic sclerosis', Japanese Journal of Clinical Immunology, vol. 33, no. 2, pp. 81-86. https://doi.org/10.2177/jsci.33.81
Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y. Involvement of mast cells in systemic sclerosis. Japanese Journal of Clinical Immunology. 2010;33(2):81-86. https://doi.org/10.2177/jsci.33.81
Yukawa, Sonosuke ; Yamaoka, Kunihiro ; Sawamukai, Norifumi ; Shimajiri, Shohei ; Saito, Kazuyoshi ; Tanaka, Yoshiya. / Involvement of mast cells in systemic sclerosis. In: Japanese Journal of Clinical Immunology. 2010 ; Vol. 33, No. 2. pp. 81-86.
@article{bd143e35da12407190d2d2a644242afc,
title = "Involvement of mast cells in systemic sclerosis",
abstract = "Systemic sclerosis is characterized by tissue fibrosis, obliterative microangiopathy and immune abnormalities. The etiology of SSc is largely unknown and is known to be resistant to existing corticosteroid and immunosuppressive drugs. Therefore, establishment of a treatment strategy especially for SSc patients with organ involvement is strongly desired. Mast cells are widely recognized as effector cells in allergic disorders and other IgE-mediated immune responses. However, recently, mast cells have become known to play a role in bridging innate immunity and adaptive immunity. Additionally, there is growing evidence of mast cell to be involved in pathogenesis of rheumatoid arthritis, and is expected as a novel therapeutic target.We describe here the role of mast cell in SSc pathology and suggest as a novel therapeutic target.",
keywords = "Imatinib, Mast cell, Pulmonary arterial hypertension, Systemic sclerosis",
author = "Sonosuke Yukawa and Kunihiro Yamaoka and Norifumi Sawamukai and Shohei Shimajiri and Kazuyoshi Saito and Yoshiya Tanaka",
year = "2010",
doi = "10.2177/jsci.33.81",
language = "English",
volume = "33",
pages = "81--86",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Involvement of mast cells in systemic sclerosis

AU - Yukawa, Sonosuke

AU - Yamaoka, Kunihiro

AU - Sawamukai, Norifumi

AU - Shimajiri, Shohei

AU - Saito, Kazuyoshi

AU - Tanaka, Yoshiya

PY - 2010

Y1 - 2010

N2 - Systemic sclerosis is characterized by tissue fibrosis, obliterative microangiopathy and immune abnormalities. The etiology of SSc is largely unknown and is known to be resistant to existing corticosteroid and immunosuppressive drugs. Therefore, establishment of a treatment strategy especially for SSc patients with organ involvement is strongly desired. Mast cells are widely recognized as effector cells in allergic disorders and other IgE-mediated immune responses. However, recently, mast cells have become known to play a role in bridging innate immunity and adaptive immunity. Additionally, there is growing evidence of mast cell to be involved in pathogenesis of rheumatoid arthritis, and is expected as a novel therapeutic target.We describe here the role of mast cell in SSc pathology and suggest as a novel therapeutic target.

AB - Systemic sclerosis is characterized by tissue fibrosis, obliterative microangiopathy and immune abnormalities. The etiology of SSc is largely unknown and is known to be resistant to existing corticosteroid and immunosuppressive drugs. Therefore, establishment of a treatment strategy especially for SSc patients with organ involvement is strongly desired. Mast cells are widely recognized as effector cells in allergic disorders and other IgE-mediated immune responses. However, recently, mast cells have become known to play a role in bridging innate immunity and adaptive immunity. Additionally, there is growing evidence of mast cell to be involved in pathogenesis of rheumatoid arthritis, and is expected as a novel therapeutic target.We describe here the role of mast cell in SSc pathology and suggest as a novel therapeutic target.

KW - Imatinib

KW - Mast cell

KW - Pulmonary arterial hypertension

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=77953661570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953661570&partnerID=8YFLogxK

U2 - 10.2177/jsci.33.81

DO - 10.2177/jsci.33.81

M3 - Article

C2 - 20453443

AN - SCOPUS:77953661570

VL - 33

SP - 81

EP - 86

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -